Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Payers Are Preparing For Coming Companion Diagnostics, Medco Notes

Executive Summary

Companion diagnostics and biomarkers were the watchwords of the recent ASCO meeting as the cancer community braces for a sea change in treatment. But as more targeted drugs and companion diagnostics make it through the clinical and regulatory arenas, payers will have to grapple with managing the more complex real-world use of these therapies.

You may also be interested in...

Personalized Medicine Takes Aim At Common Diseases

While oncology steals the limelight, some firms are harnessing the technologies and R&D strategies of precision medicine to develop combination drug/diagnostic products for large-population, non-oncology diseases.

With Personalized Medicine, Payers Want A Role In Early Development

With the development of targeted therapies and companion diagnostics increasing, AmerisourceBergen Consulting’s president advises pharma industry to bring payers in around Phase II to ensure trials give them data they need to cover drugs and diagnostics.

Quality Of Biomarkers Questioned Again; Lancet Report Calls For Better Evidence

As personalized medicine shifts from theory to practice, concerns are mounting about whether the evidence behind many biomarkers is sufficient to make pharmacogenomic testing worthwhile – suggesting sponsors should pay careful attention to providing evidence to support use of companion diagnostics.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts